Dr. Matthew Taub treats patients for a wide range of cancers as a hematologist-oncologist at Everglades Oncology and Hematology. Board-certified in his field, Dr. Matthew Taub maintains a close watch on research developments informing the oncology community.
Published in the New England Journal of Medicine, a recent study led by a University of Pittsburgh School of Medicine researcher indicates the efficacy of immunotherapy in treating triple-negative breast cancer.
As many as 20 percent of breast cancer cases involve this advanced, aggressive form of the disease, which has a relatively low survival rate and an elevated chance of metastasis and recurrence. The study involved augmenting chemotherapy with atezolizumab, an immunotherapy drug, which was well tolerated by a sample of more than 900 chemotherapy patients and brought significant clinical benefits. These included statistically significant levels of progression-free survival of 7.2 months, versus 5.5 months among those patients who received chemotherapy alone.
